Category survey

Statistical epidemiology in ageing research Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

In vivo models of disease and toxicity in the nervous system Investments > €500k United Kingdom Neurodegenerative disease in general|Prion disease 2016    

ACA5: Action decisions in health and neurodegenerative disease Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

Neurodegeneration Investments > €500k United Kingdom Huntington’s disease|Motor neurone diseases 2016    

UK Biobank Imaging Enhancement Main phase Investments > €500k United Kingdom Neurodegenerative disease in general 2016    

University of Oxford Confidence in Concept Scheme – Round 4 Investments > €500k United Kingdom Neurodegenerative disease in general 2016    

Development of a small molecule therapeutic for the treatment of prion infection of humans Investments > €500k United Kingdom Prion disease 2016    

UK Dementias Platform Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Neurodegenerative disease in general|Parkinson’s disease & PD-related disorders 2016    

Glucocerebrosidase mutations in Parkinson disease:molecular pathogenesis,and the basis for personalised therapy with small molecule chaperones Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

The role of variant (v)U1 snRNAs in development and disease. Investments > €500k United Kingdom Neurodegenerative disease in general|Spinal muscular atrophy (SMA) 2016    

Investigating mechanistic causes of C9ORF72-related amyotrophic lateral sclerosis (ALS). Investments > €500k United Kingdom Motor neurone diseases 2016    

Role of microtubule acetylation in Parkinson’s disease Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

Targeting Parkin and Mitochondrial Dynamics in Huntington’s disease Investments > €500k United Kingdom Huntington’s disease 2016    

Pathway-driven identification of therapeutic targets for combatting Alzheimer’s disease. Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Deficient Wnt signalling in synapse degeneration and its contribution to Parkinson’s Disease Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

Tackling autophagy and apoptosis for the potential therapy of Huntington’s Disease Investments > €500k United Kingdom Huntington’s disease 2016    

Dkk1-Wnt signalling pathway in synapse degeneration: implication for early stages of Alzheimer’s disease Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

HQLC Dementia Carers Instrument Development: DECIDE Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Investigating the role of Myosin VI in quality control of mitochondria linked to Parkinson’s disease pathology Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

Understanding the Molecular Origins of the Toxicity of Alpha-synuclein in Parkinson’s Disease Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

Characterising Kynurenine 3-Monooxygenase (KMO) As A Therapeutic Target For Huntington’s Disease Investments > €500k United Kingdom Huntington’s disease 2016    

Variability in human axon survival Investments > €500k United Kingdom Motor neurone diseases|Neurodegenerative disease in general 2016    

Mitochondrial ubiquitin dynamics and apoptotic cell death. Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

Predicting MRI Abnormalities with Longitudinal Data of the Whitehall II Substudy Investments > €500k United Kingdom Neurodegenerative disease in general 2016    

Neuronal- and systems-level understanding of spatial and episodic memory. Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Neurodegenerative disease in general 2016    

Pathobiology of alpha-1-antitrypsin deficency and the serpinopathies Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Neurons and biological timing Investments > €500k United Kingdom Neurodegenerative disease in general 2016    

Using genetic variability in whole transcriptome expression in cells and tissues to understand the pathogenesis of Parkinson’s and Alzheimer’s disease Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

ET-1-mediated reduction of cerebral blood flow in Alzheimer’s disease: therapeutic potential of zibotentan Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Differentiation of GMP-grade human embryonic stem cells to midbrain dopaminergic neurons for transplantation Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

Investigating a neuronal subcellular transcriptome by the novel technique of RNA TU-tagging, in a normal and ALS-related mouse model. Investments > €500k United Kingdom Motor neurone diseases 2016    

Bayesian models of expression in the transcriptome for clinical RNA-seq Investments > €500k United Kingdom Motor neurone diseases 2016    

Abeta-mediated toxicity in Alzheimer’s disease: delineating mechanisms of internalisation, cell-cell transmission and synaptic dysfunction Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Novel MRI Techniques for Brain Banking and Motor Neuron Disease Research Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

Regulation of microglial proliferation and its contribution to chronic neurodegeneration Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Prion disease 2016    

Multi-parametric and super-resolution imaging of amyloidogenic proteins Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Centre for Cognitive Ageing & Cognitive Epidemiology Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Brain imaging and cognitive ageing in the Lothian Birth Cohort 1936: III Investments > €500k United Kingdom Neurodegenerative disease in general 2016    

Million Women Study Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Neurodegenerative disease in general 2016    

DJ-1 and neurodegeneration: its roles in mitochondria and in protein misfolding Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

Roles of protein SUMOylation in AMPA receptor trafficking, synaptic dysfunction and cognitive impairment in dementia Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Machinery and Mechanisms of Endosomal Protein Sorting – A key Pathway Associated with Alzheimer Disease Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

MRC Centre for Neuropsychiatric Genetics and Genomics Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Neurodegenerative disease in general|Parkinson’s disease & PD-related disorders 2016    

Improving function in Huntington’s disease through neurofeedback: using real-time fMRI to enhance cortical plasticity in early stages of the disease Investments > €500k United Kingdom Huntington’s disease 2016    

Targeting the innate immune system in Huntington’s disease Investments > €500k United Kingdom Huntington’s disease 2016    

New humanised mouse models for dissecting the pathobiology of disease, using FUS-ALS as a paradigm Investments > €500k United Kingdom Motor neurone diseases 2016    

Manipulating mitochondrial dynamics as a potential therapeutic strategy for Parkinson’s disease Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

Using Patient Reported Outcome Measures to Assess Quality of Life in Dementia Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Understanding Effective Dementia Workforce Education and Training: A Formative Evaluation (DeWET Evaluation) Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Enhanced Creutzfeldt-Jakob Disease Surveillance in the Older Population Investments > €500k United Kingdom Prion disease 2016